Prednisone vs Placebo and Live Birth in Patients With Recurrent Implantation Failure Undergoing In Vitro Fertilization
JAMA · 2023
DOI: 10.1001/jama.2023.5302 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift JAMA, 2023. Verfasst von Yun Sun und 29 weiteren Autor:innen. Beteiligte Einrichtung: Center for Reproductive Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Hauptthemen laut MEDLINE: Fertilization in Vitro, Live Birth, Prednisone, Premature Birth. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Implantation failure remains a critical barrier to in vitro fertilization. Prednisone, as an immune-regulatory agent, is widely used to improve the probability of implantation and pregnancy, although the evidence for efficacy is inadequate.
Objective
To determine the efficacy of 10 mg of prednisone compared with placebo on live birth among women with recurrent implantation failure. Design, Setting, and Participants A double-blind, placebo-controlled, randomized clinical trial conducted at 8 fertility centers in China. Eligible women who had a history of 2 or more unsuccessful embryo transfer cycles, were younger than 38 years when oocytes were retrieved, and were planning to undergo frozen-thawed embryo transfer with the availability of good-quality embryos were enrolled from November 2018 to August 2020 (final follow-up August 2021).
Interventions
Participants were randomized (1:1) to receive oral pills containing either 10 mg of prednisone (n = 357) or matching placebo (n = 358) once daily, from the day at which they started endometrial preparation for frozen-thawed embryo transfer through early pregnancy. Main Outcomes and Measures The primary outcome was live birth, defined as the delivery of any number of neonates born at 28 or more weeks’ gestation with signs of life.
Results
Among 715 women randomized (mean age, 32 years), 714 (99.9%) had data available on live birth outcomes and were included in the primary analysis. Live birth occurred among 37.8% of women (135 of 357) in the prednisone group vs 38.8% of women (139 of 358) in the placebo group (absolute difference, −1.0% [95% CI, −8.1% to 6.1%]; relative ratio [RR], 0.97 [95% CI, 0.81 to 1.17]; P = .78). The rates of biochemical pregnancy loss were 17.3% in the prednisone group and 9.9% in the placebo group (absolute difference, 7.5% [95% CI, 0.6% to 14.3%]; RR, 1.75 [95% CI, 1.03 to 2.99]; P = .04). Of those in the prednisone group, preterm delivery occurred among 11.8% and of those in the placebo group, 5.5% of pregnancies (absolute difference, 6.3% [95% CI, 0.2% to 12.4%]; RR, 2.14 [95% CI, 1.00 to 4.58]; P = .04). There were no statistically significant between-group differences in the rates of biochemical pregnancy, clinical pregnancy, implantation, neonatal complications, congenital anomalies, other adverse events, or mean birthweights. Conclusions and Relevance Among patients with recurrent implantation failure, treatment with prednisone did not improve live birth rate compared with placebo. Data suggested that the use of prednisone may increase the risk of preterm delivery and biochemical pregnancy loss. Our results challenge the value of prednisone use in clinical practice for the treatment of recurrent implantation failure. Trial Registration Chinese Clinical Trial Registry Identifier: ChiCTR1800018783
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Reproductive Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- Shanghai Key Laboratory for Assisted Reproduction and Reproductive Genetics, Shanghai, China.
- Center for Reproductive Medicine, Shandong University, Jinan, China.
- Key Laboratory of Reproductive Endocrinology of Ministry of Education, Shandong University, Jinan, China.
- Shandong Key Laboratory of Reproductive Medicine, Jinan, China.
- Shandong Provincial Clinical Research Center for Reproductive Health, Jinan, China.
Zitieren
APA
Sun, Y., Cui, L., Lu, Y., Tan, J., Dong, X., Ni, T., Yan, J., Guan, Y., Hao, G., Liu, J. Y., Zhang, B., Wei, D., Hong, Y., He, Y., Qi, J., Xu, B., Lu, J., Zhang, Q., Zhao, S., …, & Chen, Z. J. (2023). Prednisone vs Placebo and Live Birth in Patients With Recurrent Implantation Failure Undergoing In Vitro Fertilization. JAMA. https://doi.org/10.1001/jama.2023.5302
Vancouver
Sun Y, Cui L, Lu Y, Tan J, Dong X, Ni T, et al. Prednisone vs Placebo and Live Birth in Patients With Recurrent Implantation Failure Undergoing In Vitro Fertilization. JAMA. 2023. doi:10.1001/jama.2023.5302
BibTeX
@article{Sun2023,
author = {Sun, Yun and Cui, Linlin and Lu, Yao and Tan, Jichun and Dong, Xi and Ni, Tianxiang and Yan, Junhao and Guan, Yichun and Hao, Guimin and Liu, Jia-Yin and Zhang, Bo and Wei, Daimin and Hong, Yan and He, Yaqiong and Qi, Jia and Xu, Bing and Lu, Juanjuan and Zhang, Qian and Zhao, Shanshan and Ji, Xiaowei and Du, Xiaofang and Zhang, Jie and Liu, Jinyong and Wang, Jing and Huang, Yingqin and Huang, Dongmei and Du, Yanzhi and Vankelecom, Hugo and Zhang, Heping and Chen, Zi-Jiang},
title = {Prednisone vs Placebo and Live Birth in Patients With Recurrent Implantation Failure Undergoing In Vitro Fertilization},
journal = {JAMA},
year = {2023},
doi = {10.1001/jama.2023.5302}
}
EUVIMED